Staff Contact: Kara Amann-Kale or Keri Barclay
Yesterday, the FDA updated the Pfizer COVID-19 vaccine booster dose EUA with the following details.
-
- expand the use of a single booster dose to include use in individuals ages 12 through 15
- shorten the time between the completion of primary vaccination of the Pfizer COVID-19 vaccine and a booster dose to at least five months
- allow for a third primary series dose for certain immunocompromised children 5 through 11 years of age.
The statewide standing orders have not been updated to reflect these changes. Facilities should await further guidance from the CDC and updated standing orders from DHSS, if applicable, before making the above changes to vaccination programs.
The CDC’s Advisory Committee on Immunization Practices will meet at noon Wednesday, Jan. 5, for discussion.